Clinical Trials

A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

Location:

Rochester, MN

Trial status:

Open for Enrollment

Why is this study being done?

The primary purpose of this dose escalation study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of LGH447 as a single agent when administered orally once daily to adult patients with Multiple Myeloma (MM).

Last updated: 10/15/2012

NCT ID:

NCT01456689